Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Risks of upper respiratory tract infection and pneumonia in patients with multiple myeloma receiving Daratumumab: A systematic review and meta-analysis of randomized controlled trials.

Sub-category:
Multiple Myeloma

Category:
Hematologic Malignancies—Plasma Cell Dyscrasia

Meeting:
2018 ASCO Annual Meeting

Abstract No:
e20005

Citation:
J Clin Oncol 36, 2018 (suppl; abstr e20005)

Author(s): Katy Ticona, Aung Tun, Elizabeth Guevara; The Brooklyn Hospital Center, Brooklyn, NY; Brooklyn Hospital Center, Brooklyn, NY

Abstract Disclosures

Abstract:

Background: The addition of human anti CD38 IgGκ monoclonal antibody Daratumumab (DARA) to standard multiple myeloma (MM) regimen significantly improves response rates, progression-free survival and the risk of death with notable safety concerns. We performed a systematic review & meta-analysis of RCTs to determine the risk of upper respiratory tract infection (URI) and pneumonia in MM patients receiving DARA Methods: We conducted a literature search using MEDLINE, EMBASE and SCOPUS databases using the terms “multiple myeloma AND daratumumab”, “MM AND daratumumab”, “plasma cell disorder AND daratumumab” through January 2018. The primary meta-analytic approach was a fixed effects model using the Mantel-Haenszel method. It was used to calculate the estimated pooled risk ratio (RR), and risk difference (RD) with 95% confidence interval (CI). Pooled rates of URI & pneumonia were estimated by multiplying the median follow-up duration by the sample size. Results: 1744 patients were eligible. Study arm used bortezomib (V), mephalan (M), prednisone (P) plus DARA; V, dexamethasone (D) plus DARA; and lenalidomide (R), D plus DARA. The control arm used VMP, VD, and RD. The pooled risk ratio for URI was 1.59 (95% CI: 1.33 – 1.91, P = 0.00001) and the absolute RD was 0.1 (95% CI: 0.06 – 0.14, P = 0.00001) with grade 3 or 4 RR of 1.4 (95% CI: 0.63 – 3.15, P = 0.41) and the absolute RD of 0 (95% CI: -0.01 – 0.02, P = 0.41). Pooled RR for pneumonia was 1.48 (95% CI: 1.14 - 1.93, P = 0.002) & absolute RD was 0.05 (95% CI: 0.02 - 0.08, P = 0.004) while the pooled RR for grade 3 or 4 pneumonia was 1.35 (95% CI: 0.98 – 1.86, P = 0.07) and the absolute RD was 0.02 (95% CI: -0.00 – 0.05, P = 0.07). Over median follow up of 24 months, the RR for URI was 1.46 (95% CI: 1.33 – 1.61, P < 0.00001) and RD was 0.18 (95% CI: 0.14 – 0.23, P < 0.00001) while the RR for pneumonia was 1.35 (95% CI: 1.15 – 1.58, P < 0.0003) and RD was 0.07 (95% CI: 0.03 – 0.11, P < 0.0002). Conclusions: Addition of DARA to standard MM regimen contributes a significantly higher risks of URI and pneumonia, without remarkable increase in the risks of grade 3 or 4 events.

 
Other Abstracts in this Sub-Category:

 

1. Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8000 First Author: Maria-Victoria Mateos
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

2. Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8001 First Author: Paul G. Richardson
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

3. Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8002 First Author: Ajai Chari
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

More...